logo
Quince Enters the Beauty Marketplace

Quince Enters the Beauty Marketplace

Quince, the direct-to-consumer retailer known for its accessibly-priced products across fashion, home and jewelry, has announced its foray into skincare with The Beauty Atelier by Quince, a luxury beauty marketplace that launched on Thursday morning.
The Beauty Atelier by Quince opens with an assortment of skincare best-sellers from Augustinus Bader, 111Skin and Irene Forte, with price points between $180 and $305. Shoppers earn 30 percent of their purchases back as Quince store credit.
The Atelier will live as a shop on Quince's website, and opens with a selection of 11 products comprising a selection of each brand's heroes, like Bader's Rich Cream ($305) or 111Skin's Repair Serum ($180), focussed on facial skincare. De Chatellus indicated more categories, brands and products will launch in the coming months. Purchases on The Beauty Atelier are fulfilled by the brands themselves, not Quince.
The company's objective 'is really to be the consumer destination for thoughtfully curated, high quality essentials offered up at the best value,' Daphne de Chatellus, Quince's head of emerging categories, told The Business of Beauty. 'Beauty is one of those essentials.' (The name Quince comes from 'quintessentials.')
The push into skincare is part of Quince's bigger beauty and wellness strategy. In February, the retailer released supplements; in March, it launched fine fragrances. Since its establishment in 2018, Quince has become known not only for its wide assortment of accessible luxuries but also its dupes of pricier products. The company's choice to move into boutique beauty reads as a departure.
'We did explore what it would look like if we launched our own products, and that's not to say we never will,' said Antonieta Moreland, Quince's head of brand. 'But we wanted to be really thoughtful. It helps the consumer to show them that we're partnering with people who really understand the space, which is unique compared to a cashmere sweater or linen bedding.' The Beauty Atelier by Quince will launch with skincare from three brands including Augustinus Bader and Irene Forté, with price points between $180 and $305. (Quince) Marketplace Matters
Quince is the latest retailer of its kind to turn to the marketplace model, a third-party environment where brands can reach shoppers without the fuss of wholesale.
From department stores and big box chains to specialty beauty, nearly all categories of retailers have added online marketplaces to compete with Amazon. Beauty retailers have been the latest to acknowledge the threat after the e-commerce behemoth became the US' biggest beauty retailer last year, overtaking incumbent Walmart.
The free-for-all of the marketplace model means one can reliably find third-party seller listings of classic luxuries like La Mer or new ones from Augustinus Bader on Target or Walmart. While mass retailers were the first to get in on the marketplace model, higher-end stores are increasingly following suit: Nordstrom added a marketplace in 2024, following Macy's in 2022. After losing market share last year, Ulta Beauty will be launching its own marketplace in the fall.
Retailers have recognized the model's scaling advantages, as it gives them the ability to add an unlimited number of brands without having to buy inventory or handle storage and fulfilment. Fashion e-tailers have especially struggled with managing beauty inventory — last year, Net-a-Porter scrapped its beauty wholesaling business in favor of editorial affiliate links fulfilled by the brands themselves.
'There's only so much physical real estate space in our stores,' said Ulta Beauty's chief retail officer Aimee Bayer-Thomas in an interview with Business of Beauty earlier this year, adding that the aim was an 'amplified extension' of the in-store selection.
Of course, a marketplace model also brings about issues of brand equity: Retailers trusted for their curation risk opening themselves up to unknown third-party resellers and counterfeits. Ulta Beauty's marketplace will not be an Amazon-style situation, but rather a closed platform requiring approval from the retailer to sell on it.
'We are going to take great care with our brands and thought around who is invited to participate in the marketplace. It's not just an open marketplace,' said Bayer-Thomas.
The same is true of Quince's curated marketplace, as the DTC e-tailer has sought out marketplace partners for their luxury positioning and significantly higher price points — Augustinus Bader has some products that go for just a fraction of the cost of a clothing piece from the label.
'As we look ahead to the Atelier throughout the year, we plan to expand thoughtfully into premium or prestige price points,' de Chatellus said, as the retailer expands its existing brand selection and launches new categories, including hair and body. 'This is really just the beginning.'
Sign up to The Business of Beauty newsletter, your complimentary, must-read source for the day's most important beauty and wellness news and analysis.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Quince Enters the Beauty Marketplace
Quince Enters the Beauty Marketplace

Business of Fashion

timea day ago

  • Business of Fashion

Quince Enters the Beauty Marketplace

Quince, the direct-to-consumer retailer known for its accessibly-priced products across fashion, home and jewelry, has announced its foray into skincare with The Beauty Atelier by Quince, a luxury beauty marketplace that launched on Thursday morning. The Beauty Atelier by Quince opens with an assortment of skincare best-sellers from Augustinus Bader, 111Skin and Irene Forte, with price points between $180 and $305. Shoppers earn 30 percent of their purchases back as Quince store credit. The Atelier will live as a shop on Quince's website, and opens with a selection of 11 products comprising a selection of each brand's heroes, like Bader's Rich Cream ($305) or 111Skin's Repair Serum ($180), focussed on facial skincare. De Chatellus indicated more categories, brands and products will launch in the coming months. Purchases on The Beauty Atelier are fulfilled by the brands themselves, not Quince. The company's objective 'is really to be the consumer destination for thoughtfully curated, high quality essentials offered up at the best value,' Daphne de Chatellus, Quince's head of emerging categories, told The Business of Beauty. 'Beauty is one of those essentials.' (The name Quince comes from 'quintessentials.') The push into skincare is part of Quince's bigger beauty and wellness strategy. In February, the retailer released supplements; in March, it launched fine fragrances. Since its establishment in 2018, Quince has become known not only for its wide assortment of accessible luxuries but also its dupes of pricier products. The company's choice to move into boutique beauty reads as a departure. 'We did explore what it would look like if we launched our own products, and that's not to say we never will,' said Antonieta Moreland, Quince's head of brand. 'But we wanted to be really thoughtful. It helps the consumer to show them that we're partnering with people who really understand the space, which is unique compared to a cashmere sweater or linen bedding.' The Beauty Atelier by Quince will launch with skincare from three brands including Augustinus Bader and Irene Forté, with price points between $180 and $305. (Quince) Marketplace Matters Quince is the latest retailer of its kind to turn to the marketplace model, a third-party environment where brands can reach shoppers without the fuss of wholesale. From department stores and big box chains to specialty beauty, nearly all categories of retailers have added online marketplaces to compete with Amazon. Beauty retailers have been the latest to acknowledge the threat after the e-commerce behemoth became the US' biggest beauty retailer last year, overtaking incumbent Walmart. The free-for-all of the marketplace model means one can reliably find third-party seller listings of classic luxuries like La Mer or new ones from Augustinus Bader on Target or Walmart. While mass retailers were the first to get in on the marketplace model, higher-end stores are increasingly following suit: Nordstrom added a marketplace in 2024, following Macy's in 2022. After losing market share last year, Ulta Beauty will be launching its own marketplace in the fall. Retailers have recognized the model's scaling advantages, as it gives them the ability to add an unlimited number of brands without having to buy inventory or handle storage and fulfilment. Fashion e-tailers have especially struggled with managing beauty inventory — last year, Net-a-Porter scrapped its beauty wholesaling business in favor of editorial affiliate links fulfilled by the brands themselves. 'There's only so much physical real estate space in our stores,' said Ulta Beauty's chief retail officer Aimee Bayer-Thomas in an interview with Business of Beauty earlier this year, adding that the aim was an 'amplified extension' of the in-store selection. Of course, a marketplace model also brings about issues of brand equity: Retailers trusted for their curation risk opening themselves up to unknown third-party resellers and counterfeits. Ulta Beauty's marketplace will not be an Amazon-style situation, but rather a closed platform requiring approval from the retailer to sell on it. 'We are going to take great care with our brands and thought around who is invited to participate in the marketplace. It's not just an open marketplace,' said Bayer-Thomas. The same is true of Quince's curated marketplace, as the DTC e-tailer has sought out marketplace partners for their luxury positioning and significantly higher price points — Augustinus Bader has some products that go for just a fraction of the cost of a clothing piece from the label. 'As we look ahead to the Atelier throughout the year, we plan to expand thoughtfully into premium or prestige price points,' de Chatellus said, as the retailer expands its existing brand selection and launches new categories, including hair and body. 'This is really just the beginning.' Sign up to The Business of Beauty newsletter, your complimentary, must-read source for the day's most important beauty and wellness news and analysis.

Dua Lipa Kickstarts Her Mornings With These 2 Hero Supplements
Dua Lipa Kickstarts Her Mornings With These 2 Hero Supplements

Vogue

time2 days ago

  • Vogue

Dua Lipa Kickstarts Her Mornings With These 2 Hero Supplements

Here at Vogue, we love a thought-out morning routine. Whether it's dry brushing to stimulate the lymphatic system (aka the body's internal filtration system) or swigging a shot of apple cider vinegar for blood sugar support, we're in. That's why Dua Lipa's recently revealed morning routine resonates with us so much. Sharing a video filmed in Munich before a show, Lipa broke down a day in her life—from Yoga first thing in the morning to the two small but powerful supplements she mixes in with her morning hydration. It starts as most of our days do, with a quick face wash and teeth brush, followed by slipping into some workout gear. Her exercise outfit of choice? A white stretchy two-piece. Clearly a fan of habit stacking, Lipa popped two rose gold-colored eye masks on, which, if our hunch is correct, are the Augustinus Bader The Eye Patches beloved by celebrities and beauty editors alike. Now for the wellness part. Before she pops off to a yoga class with her instructor Jessica, she adds two things to her water: Armra Colostrum's Immune Revival and LMNT's Recharge Electrolytes. After adding both sachets to two different bottles of water, she shakes them up and prepares for her workout. Between touring and non-stop travel, Lipa is clearly trying to support her immune system and energy levels. Immune Revival is a dose of bovine colostrum, a trendy supplement among the LA-wellness set, that can help to fight infection and promote good gut health. Similarly, electrolytes work to replace the minerals and vitamins that are naturally lost through sweat, exertion, and urine. Maintaining optimal levels can help with cognitive and muscular function, as well as hydration levels and fatigue. The need for a robust supplement routine is clear as Lipa progresses through the rest of her day. There are vocal and dance warm-up sessions, pre-show glam, meeting her fans, and then the main event: A riveting show. As for her nighttime routine, it's about repairing and replenishing her nervous system and skin overnight: Pure Encapsulations Magnesium Glycinate, Rejuvenated H30 Night Repair, and Gaviscon. Truly, a girl after our own heart.

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Yahoo

time3 days ago

  • Yahoo

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

SOUTH SAN FRANCISCO, Calif., June 03, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that its pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial in the rare neurodegenerative disease Ataxia-Telangiectasia (A-T) has reached an important milestone as enrollment now exceeds 75% with a total of 65 participants randomized in the study's targeted 86 participants in the six to nine year-old primary analysis population. Key Phase 3 NEAT clinical trial enrollment highlights to date include: A total of 76 participants have been enrolled, including 65 participants in the six to nine year-old primary analysis population and 11 participants aged 10 years or older. Study powering based on currently enrolled participants is approximately 80%. The rate of screening and randomization activities has materially increased with the recent activation of all study sites. A total of 108 NEAT participants have been screened to date with a low screen failure rate of 10%. All 37 NEAT participants to date have elected to transition to the NEAT open label extension (OLE) study (NCT06664853/IEDAT-04-2022). Participants who complete the full treatment period, complete study assessments, and provide informed consent are eligible to transition to the OLE study. Assuming positive study results, the company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2026. Quince was granted FDA Fast Track designation for the company's eDSP System for the treatment of patients with A-T based on the potential for eDSP to address a high unmet medical need. NEAT is an international, multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the neurological effects of Quince's lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in autologous red blood cells; previously referred to as EryDex) in patients with A-T. Participants are randomized (1:1) between eDSP or placebo and treatment consists of six infusions scheduled once every 21 to 30 days. The primary efficacy endpoint will be measured by the change from baseline to last efficacy visit in the rescored modified International Cooperative Ataxia Rating Scale (RmICARS) compared to placebo. About Ataxia-Telangiectasia A-T is an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene, which is responsible for cell homeostatic and cell division functions including but not limited to double-stranded DNA repair. Typically, A-T is first diagnosed before the age of five as children begin to develop an altered gait and fall with greater frequency. Neurological symptoms worsen and patients with A-T frequently become wheelchair-bound by adolescence. Teenage years for patients with A-T are typically marked by repeated infections, pulmonary impairment, and malignancies. The median lifespan is approximately 25 to 30 years old with mortality due to infections and malignancy. Based on IQVIA Medical Claims (Dx), PharmetricsPlus (P+), and IQVIA Analytics information, there are approximately 4,600 diagnosed patients with A-T in the U.S. Quince estimates that there are approximately 5,000 patients with A-T in the U.K. and EU4 countries. There are currently no approved therapeutic treatments in any global market for A-T. About eDSP for A-T eDSP is comprised of dexamethasone sodium phosphate (DSP) encapsulated in a patient's own red blood cells (autologous erythrocytes). DSP is a corticosteroid well known for its anti-inflammatory properties as well as its dose-limiting toxicity due to adrenal suppression. The eDSP System is designed to provide the efficacy of corticosteroids and to reduce or eliminate the significant adverse effects that accompany chronic use of corticosteroid treatment. eDSP leverages Quince's proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. Red blood cells have several characteristics that make them a potentially effective vehicle for drug delivery, including potentially better tolerability, enhanced tissue distribution, reduced immunogenicity, and prolongation of circulating half-life. Quince's AIDE technology is designed to harness these benefits to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. About Quince Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit and follow Quince on social media platforms LinkedIn, Facebook, X, and YouTube. Forward-looking Statements Statements in this news release contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements contained in this news release may be identified by the use of words such as "believe," "may," "should," "expect," "anticipate," "plan," "believe," "estimated," "potential," "intend," "will," "can," "seek," or other similar words. Examples of forward-looking statements include, among others, statements relating to the timing, success, and reporting of results of the clinical trials and related data, including plans and the ability to enroll participants, impact of closing enrollment, conduct, and/or complete current and additional studies; current and future clinical development of eDSP, including for the potential treatment of Ataxia-Telangiectasia (A-T), Duchenne muscular dystrophy (DMD), and other potential indications; the strategic development path for eDSP; planned regulatory agency submissions, including NDAs, and clinical trials and timeline, prospects, and milestone expectations; and the potential benefits of eDSP and the company's market opportunity. Forward-looking statements are based on Quince's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled "Risk Factors" in the company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 13, 2025, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince undertakes no duty to update such information except as required under applicable law. View source version on Contacts Media & Investor Contact: Stacy RoughanQuince Therapeutics, President, Corporate Communications & Investor Relationsir@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store